Skip to content

The clinical efficacy of phacoemulsification combined with goniosynechialysis using Kahook Dual Blade versus simple goniosynechialysis mechanically in the treatment of primary angle-closure glaucoma

The clinical efficacy of phacoemulsification combined with goniosynechialysis using Kahook Dual Blade versus simple goniosynechialysis mechanically in the treatment of primary angle-closure glaucoma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065075
Enrollment
Unknown
Registered
2022-10-27
Start date
2022-10-31
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

experience group:Cataract phacoemulsification+intraocular lens implantation+KDB angle separation under gonioscopy+KDB angle incision (Phaco GSL KDB)
control group:Cataract phacoemulsification+intraocular lens implantation+mechanical angle separation under gonioscopy (Phaco GSL)

Sponsors

Department of Glaucoma, Ophthalmology Center, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 65 Years

Inclusion criteria

Inclusion criteria: Sign the informed consent form and be willing to provide the visit data according to the data collection content specified in the test; 2> The patient is over 50 years old; 3> The target eye was diagnosed as primary angle closure glaucoma; Diagnostic criteria: intraocular pressure is greater than 21mmHg, and the atrial angle is at least 270 degrees adhesively closed; 4> At the same time, there was senile cataract; 5> No other eye surgery history; 6> The best corrected visual acuity (BCVA) of non target eyes was better than 20/200;

Exclusion criteria

Exclusion criteria: 1> The target eye was diagnosed as glaucoma other than primary angle closure glaucoma; 2> The target eye has received other internal eye surgery or internal eye laser treatment; 3> Have had extraocular, other serious eye diseases or eye deformities (such as microphthalmos); 4> Retinal visual acuity did not improve before surgery, or only light perception/no light perception; 5> The target eye has active eye infection or inflammation (such as conjunctivitis and scleritis); 6> Known allergy to the drug used in the study; 7> There are confirmed serious systemic diseases or any uncontrollable clinical problems, such as chronic renal failure requiring dialysis treatment, serious nervous system diseases and post organ transplantation; 8> Within three months, the patient participated in other clinical trials or was included in other clinical trials at the same time; 9> Patients in pregnancy or lactation; 10> The researchers believe that those who need to be excluded.

Design outcomes

Primary

MeasureTime frame
eye pressure;

Countries

china

Contacts

Public ContactLiu xing

Ophthalmic Center of Sun Yat-Sen University

drliuxing@163.com18922103883

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026